Immunotherapy at Any Line of Treatment Improves Survival in Patients With Advanced Metastatic Non‐small Cell Lung Cancer (NSCLC) Compared With Chemotherapy (Quijote‐CLICaP)

Thoracic Cancer - Australia
doi 10.1111/1759-7714.13272

Related search